ABCC1 and neoplasm: Moreover, our studies are the first to describe the ability of bile acids to affect ABCC1 activity and doxorubicin sensitivity in drug-resistant tumour cells in culture and in cells genetically engineered to overexpress the ABCC1 transporter.